Management Team

Chen Schor President and Chief Executive Officer

Mr. Schor joined Synta as Executive Vice President and Chief Operating Officer in December 2014, and was named President and Chief Executive Officer and appointed to the Company’s Board of Directors in May 2015. Mr. Schor has over 15 years of leadership experience in biotechnology, medical devices, business development and private equity. Mr. Schor served as Vice President, Global Branded Products Business Development and Pipeline Management at Teva Pharmaceuticals and at leadership positions in several emerging private and public companies. Mr. Schor led licensing and M&A transactions valued at over $8 billion with GSK, Amgen, Pfizer, Merck KGaA, OncoGeneX and other companies. Mr. Schor was a Partner at Yozma Venture Capital where he led the foundation and growth of multiple therapeutic companies from inception to significant commercial success and exit. Mr. Schor holds a Master in Business Administration, a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant (CPA).[Back to Top]

Chen Schor

Marc R. Schneebaum Senior Vice President, Chief Financial Officer

Mr. Schneebaum joined Synta as Senior Vice President and Chief Financial Officer in December 2014. Mr. Schneebaum brings over 25 years of experience in the biotechnology and healthcare sector to Synta. Most recently, he has served as a consultant in the healthcare industry. From 2011 to 2013, Mr. Schneebaum served as President, Chief Executive Officer and a director of Predictive BioSciences, Inc., a commercial stage cancer diagnostics company. From 1997 to 2010, he served as President, Chief Executive Officer, and a director of Sensors for Medicine and Science, Inc., an emerging medical technology company. From 1991 to 1997, he served as Senior Vice President, Finance, Business Development and Administration, and Chief Financial Officer of Genetic Therapy, Inc., a biotechnology company (acquired by Sandoz/Novartis). From 1987 to 1991, Mr. Schneebaum was a Vice President at Alex Brown & Sons Incorporated, a leading investment banking firm (now part of Deutsche Bank), where he participated in a variety of finance and strategic assignments. Mr. Schneebaum began his career in the accounting and auditing group at KPMG LLP, advancing to Senior Manager in the management consulting group. Mr. Schneebaum has served as a director of GenVec, Inc., a publicly traded biopharmaceutical company, since 2007. Mr. Schneebaum received his degree in Business Administration from the University of Maryland and is a Certified Public Accountant (inactive).[Back to Top]

Marc R. Schneebaum

Wendy E. Rieder, Esq. Senior Vice President, General Counsel

Before joining Synta in December 2002, Ms. Rieder served as the co-founder, COO and VP, Business Development and Intellectual Property of Microbiotix, Inc., a privately-held biotechnology company developing small-molecule anti-infectives. She is a registered patent attorney with experience in all aspects of business and intellectual property law relating to private and public companies in the pharmaceutical and biotechnology industries. Ms. Rieder was also the VP, Business Development and Intellectual Property at CereMedix, Inc. and LipoGenics, Inc., a patent attorney at Boehringer Ingelheim Pharmaceuticals, and a patent agent at Fish & Neave. Ms. Rieder holds an M.S. in Organic Chemistry from Columbia University and a J.D. from Fordham University. [Back to Top]

Wendy E. Rieder, Esq.

Alan C. Rigby, Ph.D. Senior Vice President, Chief Scientific Officer

Dr. Rigby joined Synta as Chief Scientific Officer in September 2015. Dr. Rigby brings over 20 years of academic and industry experience in the areas of structural biology, computational drug discovery, and translational research of small and large molecules in oncology. Most recently, Dr. Rigby served as Vice President, Global Antibody Drug Conjugate Biology at the Lilly Oncology Research Laboratory at Eli Lilly and Company in New York. Prior to joining Eli Lilly in 2010, Alan was the Principal Investigator of a National Institutes of Health (NIH) funded independent academic laboratory and the Director of the Drug Discovery and Target Validation Program within the Center for Vascular Biology at the Beth Israel Deaconess Medical Center, Harvard Medical School. Dr. Rigby has served and continues to serve on national and international granting councils including the National Institutes of Health, National Science Foundation, Canadian Foundation for Innovation and Genome Quebec’s PRIVAC. He is the North American Editor for Current Computer Aided Drug Discovery and on the Editorial Advisory Board for Future Medicinal Chemistry. He has published more than 50 scientific papers, a book chapter and has more than 10 patents that have published or are pending. Dr. Rigby holds an Honors BSc. in Biochemistry and a Ph.D. in Biochemistry from the University of Western Ontario in Canada.[Back to Top]

Adam Muzikant, Ph.D. Vice President, Business Development

Dr. Muzikant has sixteen years of leadership experience across public and private biotechnology companies, consulting, and specialty pharma. Before joining Synta in June 2015, he held business development leadership positions at AMAG Pharmaceuticals, Inotek Pharmaceuticals, EPIX Pharmaceuticals, and Predix Pharmaceuticals, and also performed transaction/strategic advisory work with Locust Walk Partners. Prior to moving into business development, Dr. Muzikant led an anti-arrhythmia drug discovery program at Predix targeting ion channels, and also led a systems biology team at Physiome Sciences creating new computer-based modeling approaches to improve drug development. Dr. Muzikant received a Ph.D. in Biomedical Engineering from Duke University and B.S. in Bioengineering from U.C. San Diego.[Back to Top]